TickerSparkInvestor Intelligence
TickerSparkInvestor Intelligence
Custom Reports
Stock Deep Dives · Free to Try
AI Analyst
Agentic Chat · Free to Try
Watchlist
Track Your Stocks · Free
Spark Charts
AI Technical Analysis · Free to Try
Intel Dashboard
Daily Trade Ideas
Trade Tracker
AI-Managed Portfolio · Pro
My Portfolio
Brokerage Connected · Pro
Custom Reports
Stock Deep Dives
AI Analyst
Agentic Chat
Watchlist
Your Stocks & Notes
Spark Charts
AI Technical Analysis
Trade Tracker
AI-Managed Portfolio
My Portfolio
Brokerage Connected
Main Feed
Today's Market Intel
Stock Reports
AI Research Reports
Top Stocks
AI-Curated Stock Lists
Commentary
Opinionated Stock Takes
Trending Stocks
Today's Big Movers
Earnings Coverage
Flashes & Deep Dives
Macro Updates
Economy & Markets
IPO Calendar
Upcoming Listings
CommunityDashboard
Log inCreate Account
← Back to TickerSpark
▌Earnings Flash·August 3, 2026

Vertex Pharmaceuticals Incorporated (VRTX) slips on earnings misses

Vertex Pharmaceuticals Incorporated (VRTX) slips after reporting earnings misses, with shares down 1.7% as investors react to the weaker-than-expected results.

Earnings FlashVRTXHealthcareBiotechnology
By TickerSpark·August 3, 2026·2 min read
Vertex Pharmaceuticals Incorporated (VRTX) slips on earnings misses
▌Key Takeaway
Vertex Pharmaceuticals Incorporated (VRTX) reported quarterly revenue of $3.33 billion, topping estimates, but EPS of $4.73 narrowly missed expectations of $4.74. Shares fell 1.68% after hours to $469.07 as investors reacted to the profit miss, making earnings execution the key issue despite the top-line beat.

Vertex Pharmaceuticals Incorporated (VRTX) Earnings Miss, Stock Slips

Vertex Pharmaceuticals Incorporated (VRTX) missed EPS estimates at $4.73 versus $4.74, beat revenue estimates at $3.33B versus $3.23B, and slipped 1.68% in after-hours trading to $469.07.

Key Numbers

  • EPS: $4.73 actual versus $4.74 estimated, a miss.

§ Product

  • How It Works
  • Custom Reports
  • AI Analyst
  • Intel Dashboard
  • Spark Charts
  • Trade Tracker
  • My Portfolio
  • Plans

§ Research

  • Main Feed
  • Community
  • Stock Reports
  • Macro Updates
  • Blog

§ Company

  • About Us
  • Contact

§ Fine Print

  • Terms of Service
  • Privacy Policy
  • Full Disclaimer
  • Cookie Policy

Notice: All content and data on TickerSpark is for informational purposes only and does not constitute financial or investment advice. All investments involve risk. Please see our Full Disclaimer for more details.

© 2026 Maxwell Cyberlogic LLC

Not Investment Advice

Made in Delaware, USA

Revenue: $3.33B actual versus $3.23B estimated, a beat.
  • After-hours reaction: $469.07, down 1.68% from the $477.10 regular-session close.
  • Trading volume: 1,447,762 shares versus an average of 1,553,964.
  • Five-quarter EPS pattern: beats in August 2025, November 2025 and May 2026; misses in February 2026 and August 2026.

    • Revenue Beat Cannot Offset the EPS Miss

    VRTX delivered a top-line beat but a bottom-line miss. Revenue at $3.33B cleared the $3.23B estimate, while EPS at $4.73 fell below $4.74. Revenue strength did not translate into an EPS beat this quarter.

    The recent pattern also argues against calling this a clean continuation. VRTX beat EPS estimates in August and November 2025 and May 2026, then missed in February 2026 and this quarter. The latest result adds a second miss to the past five quarters, even as revenue topped estimates.

    The earnings call deserves focus on management’s explanation for the revenue-EPS split. That explanation can help investors judge whether the $4.73 EPS miss reflects a one-quarter variance or a wider change in earnings execution. The negative after-hours move, with volume below average, gives the immediate market reaction, but the business read remains mixed.

    Bottom line: VRTX beat revenue estimates, but the EPS miss and 1.68% after-hours slide make profit delivery the immediate issue for the stock.

    Read the full VRTX research report
    ▌Common Questions

    Frequently asked questions

    +Why did Vertex Pharmaceuticals stock fall after earnings?
    Vertex Pharmaceuticals Incorporated (VRTX) fell 1.68% in after-hours trading to $469.07 after reporting an EPS miss. The company earned $4.73 per share versus the $4.74 estimate, even though revenue beat expectations.
    +Did Vertex Pharmaceuticals beat revenue and miss earnings?
    Yes. Vertex Pharmaceuticals Incorporated (VRTX) reported revenue of $3.33 billion, above the $3.23 billion estimate, but EPS came in at $4.73 versus the $4.74 consensus. The mixed result left investors focused on the small profit shortfall.
    +How did the market react to Vertex Pharmaceuticals' latest earnings report?
    The stock slipped 1.68% in after-hours trading to $469.07 from the regular-session close of $477.10. Trading volume was 1,447,762 shares, below the average of 1,553,964 shares.
    +What is Vertex Pharmaceuticals' recent earnings pattern?
    Over the last five quarters, Vertex Pharmaceuticals Incorporated (VRTX) posted EPS beats in August 2025, November 2025, and May 2026, then missed in February 2026 and again in August 2026. That pattern shows two misses in the past five quarters even as revenue continued to beat estimates this quarter.
    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, plus the analysis behind it. Free, in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌The Full Report

    Want the full picture on VRTX?

    The analyst-grade research report — charts, grades, valuation, and price targets — in 10 minutes.

    Read the VRTX report →Get Full Access →

    Not ready to subscribe? ·

    ▌The Full Report

    Get the full VRTX research report

    • Analyst-grade deep dive
    • Charts, valuation, grades
    • Buy/sell price targets
    Read the VRTX report →
    ▌For Active Investors

    Smarter research, on every ticker

    • Daily market intelligence
    • On-demand stock analysis
    • AI analyst chat
    Get Full Access →

    Cancel anytime

    ▌The Daily Briefing · Free

    A new stock idea, every evening.

    One stock worth watching each weekday, free in your inbox.

    Daily market recap + weekly preview. One-click unsubscribe in every email.

    ▌More on VRTX

    More to read

    All articles
    Vertex Pharmaceuticals Incorporated (VRTX) slips on deep earnings
    VRTX

    Vertex Pharmaceuticals Incorporated (VRTX) slips on deep earnings

    Vertex Pharmaceuticals Incorporated (VRTX) slips after a narrow EPS miss, but the deeper read is more nuanced: revenue beat estimates, net income stayed solid, and the cystic fibrosis franchise continued to anchor results. This analysis goes beyond the headline to examine product mix, quarterly trends, and market reaction.

    Aug 4·6 min
    Vertex just got a bigger CASGEVY market, and Wall Street may still be underestimating it
    VRTX

    Vertex just got a bigger CASGEVY market, and Wall Street may still be underestimating it

    Vertex’s CASGEVY expansion to patients as young as 2 looks like a real commercial runway extension, not a cosmetic label update. With elite margins, strong growth, and a TickerSpark Score of 89, the stock still looks built for more than a one-day pop.

    Jul 5·4 min
    Vertex Pharmaceuticals Incorporated (VRTX) rises on FDA boost
    VRTX

    Vertex Pharmaceuticals Incorporated (VRTX) rises on FDA boost

    Vertex Pharmaceuticals Incorporated (VRTX) rises after the FDA expanded CASGEVY use to younger patients, widening the therapy’s addressable market. The move lifts the stock toward its 52-week high and reinforces Vertex’s growth story beyond cystic fibrosis.

    Jul 3·6 min